We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

45 hedge funds and large institutions have $8.63M invested in VYNE Therapeutics in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 11 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

120% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 5

81% more capital invested

Capital invested by funds: $4.77M → $8.63M (+$3.86M)

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

18.64% more ownership

Funds ownership: 24.73% → 43.37% (+19%)

2% more funds holding

Funds holding: 44 → 45 (+1)

Holders
45
Holders Change
+1
Holders Change %
+2.27%
% of All Funds
0.55%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
11
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
LCM
Lynx1 Capital Management
Puerto Rico
+$950K
2
AFM
Anson Funds Management
Texas
+$707K
3
NCM
Nantahala Capital Management
Connecticut
+$583K
4
B
Braidwell
Connecticut
+$534K
5
ACM
ADAR1 Capital Management
Texas
+$473K

Top Sellers

1
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$150K
2
GCP
GSA Capital Partners
United Kingdom
-$31K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$24.8K
4
VF
Virtu Financial
New York
-$15K
5
SC
Shay Capital
New York
-$8.23K
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$13.8K – – –
Commonwealth Equity Services
27
Commonwealth Equity Services
Massachusetts
$10.9K – – –
Renaissance Technologies
28
Renaissance Technologies
New York
$10.3K +$10.1K +17,300 New
State Street
29
State Street
Massachusetts
$9.42K – – –
HIS
30
Harvest Investment Services
Illinois
$6.61K – – –
TRCT
31
Tower Research Capital (TRC)
New York
$2.11K -$23 -40 -1%
ACA
32
Acorn Capital Advisors
New York
$855 – – –
MLA
33
MB, Levis & Associates
Pennsylvania
$622 – – –
VGA
34
Vanguard Global Advisers
Pennsylvania
$600 +$586 +1,004 New
Northwestern Mutual Wealth Management
35
Northwestern Mutual Wealth Management
Wisconsin
$478 – – –
HC
36
Hurley Capital
New York
$335 – – –
Carson Wealth (CWM LLC)
37
Carson Wealth (CWM LLC)
Nebraska
$299 – – –
JP Morgan Chase
38
JP Morgan Chase
New York
$86 – – –
Wells Fargo
39
Wells Fargo
California
$39 – – –
Morgan Stanley
40
Morgan Stanley
New York
$26 – – –
TC
41
Truvestments Capital
Florida
$15 – – –
NFSG
42
Newbridge Financial Services Group
Florida
$6 – – –
LFG
43
Larson Financial Group
Missouri
$1 +$1 +2 New
Two Sigma Advisers
44
Two Sigma Advisers
New York
– -$94.6K -163,100 Closed
GCP
45
GSA Capital Partners
United Kingdom
– -$31K -53,961 Closed
VF
46
Virtu Financial
New York
– -$15K -25,327 Closed
Royal Bank of Canada
47
Royal Bank of Canada
Ontario, Canada
– -$1.42K -2,426 -99%
Bank of America
48
Bank of America
North Carolina
– -$973 -1,677 Closed
FFA
49
Farther Finance Advisors
California
– -$9 -16 Closed
1
2

VYNE Hedge Fund Activity: Q1 2026 in Review

45 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q1 2026, worth a combined $8.63M — up 81% from $4.77M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new VYNE positions and 5 closed out — a net gain of 3 holders — while 11 added to existing stakes and 5 trimmed.

The largest buyer was Lynx1 Capital Management, opening a new position worth an estimated $950K. The largest seller was Acadian Asset Management, cutting an estimated $150K.

  • 45 institutional investors held VYNE Therapeutics (VYNE) as of Q1 2026, up from 44 in Q4 2025.
  • Funds reported $8.63M of VYNE Therapeutics stock for Q1 2026, up 81% quarter-over-quarter.
  • 8 funds opened new VYNE Therapeutics positions in Q1 2026 and 5 closed out, a net change of +3 holders.
  • The largest VYNE Therapeutics buyer in Q1 2026 was Lynx1 Capital Management, an estimated $950K added.
  • The largest VYNE Therapeutics seller in Q1 2026 was Acadian Asset Management, an estimated $150K sold.

Based on aggregated 13F filings for Q1 2026.